mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines

Respirology

Volumn 13, Issue 4, 2008, Pages 510-517

  Shimizu, Junichi ^b   Horio, Yoshitsugu ^a,b   Osada, Hirotaka ^b   Hida, Toyoaki ^b   Hasegawa, Yoshinori ^b   Shimokata, Kaoru ^c   Takahashi, Takashi ^b   Sekido, Yoshitaka ^b   Yatabe, Yasushi ^b  

^a Department of Thoracic Oncology ^*  (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CHUBU UNIVERSITY   (Japan)

Author keywords

Chemosensitivity; DNA repair; DNA synthesis; Lung cancer; Predictive biomarker

Indexed keywords

CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; RIBONUCLEOTIDE REDUCTASE; TETRAZOLIUM;

ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; DEOXYCYTIDINE; DNA-BINDING PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; ENDONUCLEASES; GENE EXPRESSION PROFILING; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 44249102581     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2008.01302.x     Document Type: Article

References (44)

1. Ando M, Wakai K, Seki N, Tamakoshi A, Suzuki K et al. Attributable and absolute risk of lung cancer death by smoking status: findings from the Japan Collaborative Cohort Study. Int. J. Cancer 2003 105 : 249 54.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J et al. Cancer statistics, 2007. CA Cancer J. Clin. 2007 57 : 43 66.
3. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000 355 : 479 85.
4. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann. Oncol. 2007 18 : 317 23.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002 346 : 92 8.
6. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 2007 58 : 95 103.
7. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol. 2006 24 : 4731 7.
8. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006 355 : 983 91.
9. Zheng Z, Chen T, Li X, Haura E, Sharma A et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med. 2007 356 : 800 8.
10. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat. Rev. 1998 24 : 331 44.
11. Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003 22 : 3548 53.
12. Rosell R, Crino L, Danenberg K, Scagliotti G, Bepler G et al. Targeted therapy in combination with gemcitabine in non-small cell lung cancer. Semin. Oncol. 2003 30 : 19 25.
13. Horio Y, Hasegawa Y, Sekido Y, Takahashi M, Roth JA et al. Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells. Cancer Gene Ther. 2000 7 : 537 44.
14. Danesi R, de Braud F, Fogli S, de Pas TM, Di Paolo A et al. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol. Rev. 2003 55 : 57 103.
15. Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol. 2006 17 : 1818 25.
16. Lord RV, Brabender J, Gandara D, Alberola V, Camps C et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 2002 8 : 2286 91.
17. Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005 50 : 211 19.
18. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J. Clin. Oncol. 2007 25 : 2747 54.
19. Taillade L, Penault-Llorca F, Boulet T, Fouret P, Michiels S et al. Immunohistochemical expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann. Oncol. 2007 18 : 1043 50.
20. Pellegrini C, Falleni M, Marchetti A, Cassani B, Miozzo M et al. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin. Cancer Res. 2003 9 : 3645 52.
21. Cronin M, Pho M, Dutta D, Stephans JC, Shak S et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am. J. Pathol 2004 164 : 35 42.
22. Niedernhofer LJ, Bhagwat N, Wood RD. ERCC1 and non-small-cell lung cancer. N. Engl. J. Med. 2007 356 : 2538 40 author reply 40-1.
23. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 2004 64 : 3761 6.
24. Dumontet C, Fabianowska-Majewska K, Mantincic D, Callet Bauchu E, Tigaud I et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br. J. Haematol. 1999 106 : 78 85.
25. Goan YG, Zhou B, Hu E, Mi S, Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res. 1999 59 : 4204 7.
26. Jordheim LP, Guittet O, Lepoivre M, Galmarini CM, Dumontet C. Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol. Cancer Ther 2005 4 : 1268 76.
27. Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res. 2005 65 : 9510 16.
28. Bepler G, Sharma S, Cantor A, Gautam A, Haura E et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J. Clin. Oncol. 2004 22 : 1878 85.
29. Rosell R, Felip E, Taron M, Majo J, Mendez P et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin. Cancer Res. 2004 10 : 4215s 19s.
30. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells. role of ERCC1-XPF. Biochem. Pharmacol. 2000 60 : 1305 13.
31. Lee KB, Parker RJ, Bohr V, Cornelison T, Reed E. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 1993 14 : 2177 80.
32. Yang LY, Li L, Jiang H, Shen Y, Plunkett W. Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin. Cancer Res. 2000 6 : 773 81.
33. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest. 1994 94 : 703 8.
34. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol. 1998 16 : 309 16.
35. Warnecke-Eberz U, Metzger R, Miyazono F, Baldus SE, Neiss S et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin. Cancer Res. 2004 10 : 3794 9.
36. Booton R, Ward T, Ashcroft L, Morris J, Heighway J et al. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J. Thorac. Oncol. 2007 2 : 902 6.
37. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005 127 : 978 83.
38. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol. 2004 22 : 2594 601.
39. Aloyz R, Xu ZY, Bello V, Bergeron J, Han FY et al. Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res. 2002 62 : 5457 62.
40. van der Lee I, Smit EF, van Putten JW, Groen HJ, Schlosser NJ et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann. Oncol. 2001 12 : 557 61.
41. Masters GA, Declerck L, Blanke C, Sandler A, DeVore R et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J. Clin. Oncol. 2003 21 : 1550 5.
42. Gemma A, Li C, Sugiyama Y, Matsuda K, Seike Y et al. Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database. BMC Cancer 2006 6 : 174.
43. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 2000 24 : 236 44.
44. Minna JD, Girard L, Xie Y. Tumor mRNA expression profiles predict responses to chemotherapy. J. Clin. Oncol. 2007 25 : 4329 36.